"phase i" trang 4 - tải miễn phí từ tailieunhanh
Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®

Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®
13    47    0
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
8    47    0
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: Phase I dose escalation pharmacokinetic study

Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: Phase I dose escalation pharmacokinetic study
9    52    0
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
6    45    1
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
11    70    1
Chemoradiation in elderly esophageal cancer patients: Rationale and design of a phase I/II multicenter study (OSAGE)

Chemoradiation in elderly esophageal cancer patients: Rationale and design of a phase I/II multicenter study (OSAGE)
8    77    1
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study
7    60    1
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
9    27    1
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
8    62    1
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: The combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: The combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
11    58    1
The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
9    56    1
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An openlabel, phase I trial with an extensive biomarker program

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An openlabel, phase I trial with an extensive biomarker program
10    63    1
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: Preliminary results of safety, durable survival and immune biomarkers

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: Preliminary results of safety, durable survival and immune biomarkers
11    37    2
Ixazomib in combination with carboplatin in pretreated women with advanced triplenegative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Ixazomib in combination with carboplatin in pretreated women with advanced triplenegative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
9    60    1
‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment

‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment
8    71    1
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
13    35    1
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma

A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
8    39    1
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
8    46    1
A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer

A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer
8    74    1
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
10    64    1